The Flow Cytometry Facility (FCF) is a Shared Resource that provides Cancer Center investigators access to high quality, cost effective flow cytometry services and technology. By providing these services and the scientific expertise necessary to effectively use this technology, the facility serves to enhance the scope and quality of cancer research performed at the University. With state of the art instrumentation, the facility offers high speed 4 way cell sorting and cloning, complex multicolor analytical services, multiplexing assays for soluble analytes, and imaging flow cytometry. This instrumentation is compatible with a wide variety of flow cytometric applications such as subpopulation identification/quantification, molecular detection (using labeled antibodies or other ligands or fluorescent protein reporter molecules), measurement of DNA and RNA content for cell cycle analysis, apoptosis, transcriptional activity, intracellular ion concentration (e.g. Ca++), cell viability, membrane potential, microarrays, and bead based immunoassays. In addition to the instrumentation, the highly experienced staff of the FCF provides consultation in experimental design, sample preparation and data analysis. Researchers have the option, once trained, of performing their own analysis or utilizing the expertise of the facility's staff to run their samples for them. Specialized training classes are offered for those researchers who wish to better understand the principles and techniques employed in this technology and prefer to directly acquire and/or analyze their own samples. The services and expertise offered by the FCF play a key role in the study of many types of cancer, especially hematological malignancies, as well as immune responses to cancers.

Public Health Relevance

Flow cytometry is a mainstay of research on the immune system, and has now broadened its utility to all aspects of cancer research where analysis of single cells is important. As we learn more about the heterogeneity of tumors, this becomes increasingly critical for modern cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-23
Application #
8635294
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
23
Fiscal Year
2014
Total Cost
$44,556
Indirect Cost
$19,017
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437

Showing the most recent 10 out of 539 publications